Dongkook Pharmaceutical, citing increased outdoor activity in spring, on the 12th suggested ways to help prevent allergic rhinitis symptoms and support energy and recovery from fatigue.
Co&Tech, an ointment-type nasal barrier product, is an avoidance-therapy product made with medical-grade white soft paraffin that has completed biocompatibility testing. It helps form a protective layer on the nasal mucosa to block the penetration of allergens inhaled through the respiratory tract. For people feeling run down by a busy routine, the company said the over-the-counter Argishot Solution can help replenish energy. Arginine is an amino acid involved in vasodilation and improved blood flow and may help relieve fatigue and boost vitality.
SenseOn Active Up, a premium supplement containing magnesium and active vitamins, may help with muscle relaxation and recovery from physical fatigue. It contains more than 350 mg of magnesium, the recommended daily intake, and includes 138 mg of active vitamin B1 (benfotiamine), described as an optimal daily intake level to improve bioavailability. For those needing faster recovery during outdoor activities, the company said SenseOn Speed Double Action Solution, sold in stick packs, can be taken conveniently.
Daewon Pharmaceutical said on the 12th it has expanded its high-content Albumin King brand with the launch of Liposomal Albumin King, designed to improve absorption in the body.
The product applies the company’s “liposome formulation technology,” which wraps nutrients in phospholipids similar to human cell membranes. The company said the approach helps deliver nutrients more stably and can increase absorption compared with conventional formulations.
As its main ingredient, the product uses a 100% albumin complex that underwent strict quality control, the company said. Liposomal Albumin King contains 33,000 mg of high-protein formulation per bottle (ampoule) and keeps the liquid ampoule format that has been popular, it added.
Magok CHA Hospital’s fertility center said on the 12th it received the Health and Welfare Ministry’s certification as a “medical institution for attracting foreign patients.” The certification is granted to institutions that meet standards for international medical capability, patient safety and service quality.
The center operates a dedicated treatment area for international patients, called Building B. It provides one-on-one consultations and assigns professional interpreters to support tailored care. The hospital said it has a system for consultations in multiple languages, including English and Chinese, as well as Mongolian, Japanese and Russian.
Medical staff provide specialized consultations and individualized treatment plans, while a global communication team supports the process in a one-stop service, from scheduling to linking consultations and tests and providing protocol services. The hospital also cited airport access and medical-tourism infrastructure as strengths.
Huons said on the 12th it received approval from the Ministry of Food and Drug Safety on March 11 for an investigational new drug application for a Phase 2 clinical trial of HUC1-394, a new drug candidate for dry eye disease. HUC1-394 is a peptide-based eye drop Huons licensed from Novacell Technology.
The candidate selectively binds to and activates formyl peptide receptor 2, a receptor involved in the body’s inflammation-resolution process, the company said. By helping repair damaged tissue and improving keratoconjunctivitis, or inflammation of the cornea and conjunctiva, it is expected to address dry eye disease at its root, it added.
Huons said it previously demonstrated safety and tolerability in a Phase 1 trial last year involving 60 healthy adults. No serious adverse events occurred after single and repeated dosing, the company said, providing sufficient basis for follow-up trials.
With the Phase 2 plan approved, Huons will conduct a multicenter, randomized, double-blind (RCT) trial in 150 dry-eye patients at major medical institutions including Severance Hospital at Yonsei University College of Medicine. The study will assess safety and efficacy and explore the optimal dosing regimen.
Alteogen said on the 12th it registered with the U.S. Patent and Trademark Office a composition patent related to a subcutaneous Keytruda product that combines its Hybrozyme platform-based ALT-B4 (berahyaluronidase alfa) with Keytruda (pembrolizumab).
Under the patent, the subcutaneous formulation of Keytruda using ALT-B4, marketed as Keytruda Qurex, will be protected in the United States until early 2043, or about 17 years, the company said.
Keytruda Qurex received approval from the U.S. Food and Drug Administration in September and is now sold in the United States, Alteogen said. The company said it can receive up to $1 billion in sales milestones based on annual and cumulative revenue, followed by sales-based royalties.
Alteogen said the patent is part of its broader portfolio strategy to strengthen protection of the Hybrozyme platform, adding that the registration again confirms the novelty and proprietary invention of ALT-B4.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.